Indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
FDA Approval
2017-11-06
FDA
3 therapies
Page 1 of 1
Page 1 of 1